Features Identified in Induction Failure Among Childhood ALL

Findings from a new study appearing in the latest issue of the New England Journal of Medicine indicate that researchers are getting closer to identifying those indicators in childhood acute lymphoblastic leukemia (ALL) that tend to mean a poorer prognosis following induction treatment failure.

The study, by lead author Martin Schrappe MD, Chair of the International BFM (Berlin-Frankfurt-Munster) Study Group, examined records from newly diagnosed ALL patients who were treated by a total of 14 cooperative study groups between 1985 and 2000. They analyzed the relationships among disease characteristics, treatments administered, and outcomes in these patients.

What they determined was that patients with induction failure frequently presented with high-risk features, including:

-- Older age
--High leukocyte count
--Leukemia with a T-cell phenotype
--Philadelphia chromosome
--11q23 rearrangement

At a median follow-up period of 8.3 years, the 10-year survival rate was at only around 32%.

Cases in which the patient was aged 10 or older with T-cell leukemia, the presence of an 11q23 rearrangement, and 25% or more blasts in the bone marrow at the end of induction therapy were associated with a particularly poor outcome.

High hyperdiploidy and an age of 1 to 5 years were associated with a favorable outcome in patients with precursor B-cell leukemia.

Allogeneic stem-cell transplantation from matched, related donors was also associated with improved outcomes in T-cell leukemia.

Those patients who are younger than six with precursor B-cell leukemia and no adverse genetic features had a 10-year survival rate of over 72 percent when treated with chemotherapy.

Source: NEJM

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap